Cell Source Inc.

CLCS

⚠ Showing the latest available close (Nov 4, 2026, 2 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.

Since our inception, we have been involved with the development of proprietary immune system management technology ( Cell Source technology ) licensed from Yeda Research & Development Company Limited ( Yeda ), the commercial arm of the Weizmann Institute of Science ( Weizmann Institute ) in Israel. The current focus of our Research and Development efforts is at the University of Texas MD Anders…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$35M

EPS-$0.14

P/E-3.71

P/FCF-11.36

EV/EBITDA-9.63

FCF Yield–

Div. Yield–

Net Debt/FCF-0.1x

Cell Source Inc. intrinsic value

52-Week Range

$0.33$0.99

Profitability & Returns

TTM as of 2025-03 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$5M

▲ +15.2% YoY

Op. Margin

–

ROIC

-907.59%

▼ -1600.3pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$3M

▼ -14.3% YoY

Op. Cash Flow (TTM)

-$3M

▼ -14.3% YoY

Net Debt

$314K

Cash & Equiv.

$1K

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with CLCS

CompareIntrinsic value

CBIOCrescent Biopharma, Inc.

$12.94-6.37%50

AYTUAytu BioPharma Inc.

$1.81-5.73%48

JNJJohnson & Johnson

$272.32-1.45%53

ORGSOrgenesis Inc.

$0.49+949.25%20

LGVNLongeveron Inc.

$1.71-3.93%10

ALXOAlx Oncology Holdings Inc.

$1.15-15.44%10

BPTHBio-Path Holdings Inc.

$0.00-40.00%20

CYDYCytoDyn Inc.

$0.23-1.83%0

Cell Source (CLCS) in three numbers

Quality score: 0/100; Best check: share count change, 91.0%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -3.71; Negative: a loss over the last twelve months. Price to free cash flow -11.36.; Financials

Questions about Cell Source

Is Cell Source a high-quality business?

Cell Source scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is share count change at 91.0%. The Quality tab shows every check against its target.

Does Cell Source (CLCS) pay a dividend?

No. Cell Source (CLCS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 13 May 2026 (period ending 31 Mar 2025), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in CLCS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CLCS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.